Keeping Calm In Stresa
Greetings from Stresa Italy, a gorgeous town on the edge of Lake Maggiore. With great food, excellent wines and friendly people, Italy is always...
Sean Doherty Joins Provention Bio Board of Directors
Tailwinds' Take: this is a very high quality addition to the board and lends a ton of credence to their diabetes programs.
OLDWICK, N.J., Sept....
Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing
OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today...
Volatility Creating Opportunity…
I tend to be very much a buy and hold investor. I take positions, add to them as I gain confidence and generally let...
Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock
Tailwinds' Take: PRVB finally ripped the bandaid off and raised this money. A couple key takeaways.
The headline says $40 million, but the...
Fall Investor Preview Along With A Belated August Recap
I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences...
Why Provention Bio Is In My Portfolio
Quite often when I write about companies I'm just about the only one doing so. It's in these situations that Tailwinds can add value...
If I Had A Nickel For Every Buying Opportunity…
The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you...
Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus
OLDWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that...
Provention Bio Reports Second Quarter 2019 Financial Results
OLDWICK, N.J., Aug. 6, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial...
Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay...
OLDWICK, N.J., Aug. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that...
A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk...
OLDWICK, N.J., June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that...